Moderna Unveils Promising Data on mRNA Therapies for Inborn Metabolic Disorders at 2025 ICIEM Congress

Reuters

09/02

<a href="https://laohu8.com/S/MRNA">Moderna</a> Unveils Promising Data on mRNA Therapies for Inborn Metabolic Disorders at 2025 ICIEM Congress

Moderna Inc. has announced the acceptance of five abstracts for presentation at the 2025 International Congress of Inborn Errors of Metabolism (ICIEM) in Kyoto, Japan, from September 2-6, 2025. These presentations will provide insights into Moderna's investigational mRNA therapeutics targeting propionic acidemia (PA), methylmalonic acidemia $(MMA)$, and Glycogen Storage Disease Type 1a (GSD1a). The presentations will include three oral and two poster sessions, marking the first time the company will showcase data on MMA and GSD1a at a scientific congress. Highlights include interim data on mRNA-3705 for MMA and final results from the mRNA-3927-P101 study for PA, as well as updates from the Phase 1/2 Ba1ance Study for GSD1a. The presentations will feature contributions from researchers such as Yoko Nakajima, Sabine Fuchs, and Andreas Schulze.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1067089) on September 02, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2564096348"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2564096348\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2564096348?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-02 19:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2564096348","market":"fut","top_or_hot":-1,"title":"Moderna Unveils Promising Data on mRNA Therapies for Inborn Metabolic Disorders at 2025 ICIEM Congress","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MRNA\">Moderna</a> Unveils Promising Data on mRNA Therapies for Inborn Metabolic Disorders at 2025 ICIEM Congress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Moderna Inc. has announced the acceptance of five abstracts for presentation at the 2025 International Congress of Inborn Errors of Metabolism (ICIEM) in Kyoto, Japan, from September 2-6, 2025. These presentations will provide insights into Moderna's investigational mRNA therapeutics targeting propionic acidemia (PA), methylmalonic acidemia <a href=\"https://laohu8.com/S/MMA\">$(MMA)$</a>, and Glycogen Storage Disease Type 1a (GSD1a). The presentations will include three oral and two poster sessions, marking the first time the company will showcase data on MMA and GSD1a at a scientific congress. Highlights include interim data on mRNA-3705 for MMA and final results from the mRNA-3927-P101 study for PA, as well as updates from the Phase 1/2 Ba1ance Study for GSD1a. The presentations will feature contributions from researchers such as Yoko Nakajima, Sabine Fuchs, and Andreas Schulze.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1067089) on September 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Unveils Promising Data on mRNA Therapies for Inborn Metabolic Disorders at 2025 ICIEM Congress</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Unveils Promising Data on mRNA Therapies for Inborn Metabolic Disorders at 2025 ICIEM Congress\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-09-02 19:06</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/MRNA\">Moderna</a> Unveils Promising Data on mRNA Therapies for Inborn Metabolic Disorders at 2025 ICIEM Congress\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Moderna Inc. has announced the acceptance of five abstracts for presentation at the 2025 International Congress of Inborn Errors of Metabolism (ICIEM) in Kyoto, Japan, from September 2-6, 2025. These presentations will provide insights into Moderna's investigational mRNA therapeutics targeting propionic acidemia (PA), methylmalonic acidemia <a href=\"https://laohu8.com/S/MMA\">$(MMA)$</a>, and Glycogen Storage Disease Type 1a (GSD1a). The presentations will include three oral and two poster sessions, marking the first time the company will showcase data on MMA and GSD1a at a scientific congress. Highlights include interim data on mRNA-3705 for MMA and final results from the mRNA-3927-P101 study for PA, as well as updates from the Phase 1/2 Ba1ance Study for GSD1a. The presentations will feature contributions from researchers such as Yoko Nakajima, Sabine Fuchs, and Andreas Schulze.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1067089) on September 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nNDL728R76:1","article_id":"2564096348","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2564096348","pubTimestamp":1756811162,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Moderna Inc. has announced the acceptance of five abstracts for presentation at the 2025 International Congress of Inborn Errors of Metabolism  in Kyoto, Japan, from September 2-6, 2025. These presentations will provide insights into Moderna's investigational mRNA therapeutics targeting propionic acidemia , methylmalonic acidemia , and Glycogen Storage Disease Type 1a . The presentations will include three oral and two poster sessions, marking the first time the company will showcase data on MMA and GSD1a at a scientific congress. Highlights include interim data on mRNA-3705 for MMA and final results from the mRNA-3927-P101 study for PA, as well as updates from the Phase 1/2 Ba1ance Study for GSD1a. The presentations will feature contributions from researchers such as Yoko Nakajima, Sabine Fuchs, and Andreas Schulze.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, thi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","BK4551":"寇图资本持仓","BK4568":"美国抗疫概念","BK4534":"瑞士信贷持仓","BK4548":"巴美列捷福持仓","BK4532":"文艺复兴科技持仓","MRNA":"Moderna, Inc.","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4588":"碎股","BK4501":"段永平概念"},"translate_title":"Moderna在2025年ICIEM大会上公布了有关先天性代谢障碍mRNA疗法的有希望的数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9},"content_text":"Moderna Unveils Promising Data on mRNA Therapies for Inborn Metabolic Disorders at 2025 ICIEM Congress\n    \n\n        Moderna Inc. has announced the acceptance of five abstracts for presentation at the 2025 International Congress of Inborn Errors of Metabolism (ICIEM) in Kyoto, Japan, from September 2-6, 2025. These presentations will provide insights into Moderna's investigational mRNA therapeutics targeting propionic acidemia (PA), methylmalonic acidemia $(MMA)$, and Glycogen Storage Disease Type 1a (GSD1a). The presentations will include three oral and two poster sessions, marking the first time the company will showcase data on MMA and GSD1a at a scientific congress. Highlights include interim data on mRNA-3705 for MMA and final results from the mRNA-3927-P101 study for PA, as well as updates from the Phase 1/2 Ba1ance Study for GSD1a. The presentations will feature contributions from researchers such as Yoko Nakajima, Sabine Fuchs, and Andreas Schulze.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1067089) on September 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}